{
    "name": "deucravacitinib",
    "comment": "Rx",
    "other_names": [
        "Sotyktu"
    ],
    "classes": [
        "Dermatologics",
        "Tyrosine Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/sotyktu-deucravacitinib-4000276",
    "pregnancy": {
        "common": [
            "Insufficient data are available from case reports on use during pregnancy to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome",
            "Report pregnancies to Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No effects on embryofetal development were observed with oral administration to rats and rabbits during organogenesis at doses that were at least 91x the maximum recommended human dose of 6 mg once daily "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence in human milk, effects on breastfed infant, or effects on milk production",
            "Present in rat milk; when a drug is present in animal milk, it is likely that it will be present in human milk "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to deucravacitinib or any of excipients in drug product"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, angioedema) have been reported; if a clinically significant reaction occurs, discontinue therapy",
                "Evaluate for TB before initiating ",
                "Malignancies, including lymphomas, were observed; consider the benefits and risk for individual, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy during treatment",
                "Cases of rhabdomyolysis reported resulting in interrupting or discontinuing therapy; discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed or suspected; advise patients to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever",
                "May increase triglyceride levels; monitor and manage according to clinical guidelines for hyperlipidemia",
                "Elevated liver enzymes have been reported; evaluate liver enzymes at baseline and then monitor in patients with known or suspected liver disease; if liver enzymes increase or drug-induced liver injury suspected; interrupt therapy until liver injury is ruled out",
                "Before initiating, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination"
            ],
            "specific": [
                {
                    "type": "Infections",
                    "description": [
                        "May increase infection risk; avoid use with active or serious infections, including localized infections ",
                        "Closely monitor for developing signs and symptoms of infection during and after treatment ",
                        "If infection develops, promptly evaluate and complete diagnostic testing ",
                        "Initiate appropriate antimicrobial therapy and closely monitor ",
                        "Interrupt therapy if serious infection develops; do not resume until infection resolves or is adequately treated ",
                        "Consider risks and benefits of therapy before initiating in patients",
                        "With chronic or recurrent infection",
                        "Who have been exposed to tuberculosis",
                        "With a history of a serious or an opportunistic infection",
                        "With underlying conditions that may predispose them to infection",
                        "Viral reactivation",
                        "Herpes virus reactivation (eg, herpes zoster, herpes simplex), was reported ",
                        "Impact on chronic viral hepatitis reactivation is unknown ",
                        "Patients who tested positive for hepatitis B or C, chronic hepatitis B, or untreated hepatitis C were excluded from clinical trials ",
                        "Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before initiating and during therapy ",
                        "If signs of reactivation occur, consult a hepatitis specialist ",
                        "Not recommended for use in patients with active hepatitis B or hepatitis C "
                    ]
                },
                {
                    "type": "Potential risks related to Janus kinase (JAK) inhibitors",
                    "description": [
                        "Unknown whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition",
                        "In a safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients aged ≥50 years with at least 1 cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor ",
                        "Not approved for use in RA"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Vaccinations",
                        "Live vaccines: Avoid use",
                        "Response to live or non-live vaccines not evaluated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and deucravacitinib both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infections",
            "percent": "29"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "19.2"
        },
        {
            "name": "Blood creatine phosphokinase increased",
            "percent": "2.7"
        },
        {
            "name": "Herpes simplex",
            "percent": "2"
        },
        {
            "name": "Mouth ulcers",
            "percent": "1.9"
        },
        {
            "name": "Folliculitis",
            "percent": "1.7"
        },
        {
            "name": "Acne",
            "percent": "1.4"
        },
        {
            "name": "Herpes zoster",
            "percent": null
        }
    ]
}